Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
2.020
-0.100 (-4.72%)
At close: Dec 16, 2025, 4:00 PM EST
2.020
0.00 (0.00%)
Pre-market: Dec 17, 2025, 8:44 AM EST
PACB Revenue
In the year 2024, Pacific Biosciences of California had annual revenue of $11.70M, down -2.99%. Pacific Biosciences of California had revenue of $2.82M in the quarter ending December 31, 2024, a decrease of -6.97%.
Revenue (ttm)
$11.70M
Revenue Growth
-2.99%
P/S Ratio
3.86
Revenue / Employee
$268,842
Employees
575
Market Cap
609.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.70M | -361.00K | -2.99% |
| Dec 31, 2023 | 12.06M | -693.00K | -5.43% |
| Dec 31, 2022 | 12.75M | 970.00K | 8.23% |
| Dec 31, 2021 | 11.78M | 617.00K | 5.53% |
| Dec 31, 2020 | 11.17M | 1.87M | 20.09% |
| Dec 31, 2019 | 9.30M | 3.63M | 63.97% |
| Dec 31, 2018 | 5.67M | 1.49M | 35.74% |
| Dec 31, 2017 | 4.18M | 3.93M | 1,597.97% |
| Dec 31, 2016 | 246.00K | 99.00K | 67.35% |
| Dec 31, 2015 | 147.00K | 25.00K | 20.49% |
| Dec 31, 2014 | 122.00K | 74.00K | 154.17% |
| Dec 31, 2013 | 48.00K | -188.00K | -79.66% |
| Jul 31, 2012 | 236.00K | -885.17K | -78.95% |
| Jul 31, 2011 | 1.12M | -1.12M | -50.07% |
| Jul 31, 2010 | 2.25M | 975.74K | 76.84% |
| Jul 31, 2009 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PACB News
- 18 days ago - PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes - GlobeNewsWire
- 6 weeks ago - PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China - GlobeNewsWire
- 7 weeks ago - PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 2 months ago - PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities - GlobeNewsWire
- 2 months ago - PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project - GlobeNewsWire
- 2 months ago - Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity - GlobeNewsWire